Cue Biopharma, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M |
| Operating income | -$26.6M | -$41.5M | -$52.1M | -$53.2M | -$43.7M |
| Operating expenses | $54.0M | $50.8M | $57.6M | $54.5M | $58.7M |
| Cash from operations | -$21.7M | -$36.3M | -$40.0M | -$41.8M | -$38.8M |
| Capital expenditure | $177,000 | $66,000 | $0 | $171,000 | $913,039 |
| Free cash flow | -$21.9M | -$36.4M | -$40.0M | -$42.0M | -$39.8M |
| Share repurchases | — | — | $0 | $200,000 | $750,128 |
| Total assets | $42.2M | $32.2M | $61.5M | $91.3M | $83.4M |
| Total liabilities | $15.8M | $14.7M | $24.4M | $25.6M | $17.9M |
| Total debt | — | — | $8.0M | $10.0M | — |
Shares outstanding 4.0M · Free float 56.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.